Incidental Findings of Coexisting Metastatic Pancreatic Cancer in Patients with Prostate Cancer on 18F-Prostate-Specific Membrane Antigen PET/CT

Yang Lu; Chun Li

doi:10.1097/RLU.0000000000004338

Incidental Findings of Coexisting Metastatic Pancreatic Cancer in Patients with Prostate Cancer on ¹⁸F-Prostate-Specific Membrane Antigen PET/CT

Yang Lu, Chun Li

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

A 79-year-old man with rising prostate-specific antigen of 3.2 ng/mL and diagnosis of metastatic castration-resistant prostate cancer received abiraterone and prednisone for treatment regarding prostate-specific membrane antigen (PSMA)-avid bone lesions on PET/CT. Four months later, a follow-up 18F-DCFPyL PET/CT demonstrated new and increased multifocal PSMA-avid osseous and liver lesions, whereas prostate-specific antigen was stabled at 3.1 ng/mL. Biopsy of liver lesion showed metastasis from a primary pancreatic acinar cell carcinoma. Retrospectively, PSMA-avid pancreatic body lesion was identified on both PSMA PET/CT scans. This case illustrated that any above background PSMA uptake in the pancreas warrants suspicion for malignancy.

Original language	English (US)
Pages (from-to)	1103-1104
Number of pages	2
Journal	Clinical nuclear medicine
Volume	47
Issue number	12
DOIs	https://doi.org/10.1097/RLU.0000000000004338
State	Published - Dec 1 2022

Keywords

PET/CT
PSMA
metastasis
pancreatic cancer
prostate cancer

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000004338

Cite this

@article{1a737e04baf04bd5bf32bd2c2f09b6be,

title = "Incidental Findings of Coexisting Metastatic Pancreatic Cancer in Patients with Prostate Cancer on 18F-Prostate-Specific Membrane Antigen PET/CT",

abstract = "A 79-year-old man with rising prostate-specific antigen of 3.2 ng/mL and diagnosis of metastatic castration-resistant prostate cancer received abiraterone and prednisone for treatment regarding prostate-specific membrane antigen (PSMA)-avid bone lesions on PET/CT. Four months later, a follow-up 18F-DCFPyL PET/CT demonstrated new and increased multifocal PSMA-avid osseous and liver lesions, whereas prostate-specific antigen was stabled at 3.1 ng/mL. Biopsy of liver lesion showed metastasis from a primary pancreatic acinar cell carcinoma. Retrospectively, PSMA-avid pancreatic body lesion was identified on both PSMA PET/CT scans. This case illustrated that any above background PSMA uptake in the pancreas warrants suspicion for malignancy.",

keywords = "PET/CT, PSMA, metastasis, pancreatic cancer, prostate cancer",

author = "Yang Lu and Chun Li",

year = "2022",

month = dec,

day = "1",

doi = "10.1097/RLU.0000000000004338",

language = "English (US)",

volume = "47",

pages = "1103--1104",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "12",

}

TY - JOUR

T1 - Incidental Findings of Coexisting Metastatic Pancreatic Cancer in Patients with Prostate Cancer on 18F-Prostate-Specific Membrane Antigen PET/CT

AU - Lu, Yang

AU - Li, Chun

PY - 2022/12/1

Y1 - 2022/12/1

N2 - A 79-year-old man with rising prostate-specific antigen of 3.2 ng/mL and diagnosis of metastatic castration-resistant prostate cancer received abiraterone and prednisone for treatment regarding prostate-specific membrane antigen (PSMA)-avid bone lesions on PET/CT. Four months later, a follow-up 18F-DCFPyL PET/CT demonstrated new and increased multifocal PSMA-avid osseous and liver lesions, whereas prostate-specific antigen was stabled at 3.1 ng/mL. Biopsy of liver lesion showed metastasis from a primary pancreatic acinar cell carcinoma. Retrospectively, PSMA-avid pancreatic body lesion was identified on both PSMA PET/CT scans. This case illustrated that any above background PSMA uptake in the pancreas warrants suspicion for malignancy.

AB - A 79-year-old man with rising prostate-specific antigen of 3.2 ng/mL and diagnosis of metastatic castration-resistant prostate cancer received abiraterone and prednisone for treatment regarding prostate-specific membrane antigen (PSMA)-avid bone lesions on PET/CT. Four months later, a follow-up 18F-DCFPyL PET/CT demonstrated new and increased multifocal PSMA-avid osseous and liver lesions, whereas prostate-specific antigen was stabled at 3.1 ng/mL. Biopsy of liver lesion showed metastasis from a primary pancreatic acinar cell carcinoma. Retrospectively, PSMA-avid pancreatic body lesion was identified on both PSMA PET/CT scans. This case illustrated that any above background PSMA uptake in the pancreas warrants suspicion for malignancy.

KW - PET/CT

KW - PSMA

KW - metastasis

KW - pancreatic cancer

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85141696940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141696940&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000004338

DO - 10.1097/RLU.0000000000004338

M3 - Article

C2 - 35835124

AN - SCOPUS:85141696940

SN - 0363-9762

VL - 47

SP - 1103

EP - 1104

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 12

ER -